Skip to main content
Premium Trial:

Request an Annual Quote

Sequenta, Illumina Strike IVD Deal for NGS-based Test to Monitor Residual Disease

NEW YORK (GenomeWeb) – Sequenta and Illumina have struck an agreement to commercialize an in vitro diagnostic kit based on Sequenta's minimal residual disease detection and quantification technology.

Sequenta launched a laboratory-developed test dubbed ClonoSight last year. The test uses proprietary technology to target immune cells and measure MRD in leukemia and lymphoma patients.

"Partnering with Illumina to develop an IVD kit will ultimately enable more doctors to use the prognostic power of Sequenta's MRD detection and quantification technology in caring for their patients," Tom Willis, CEO of Sequenta, said in a statement.

Sequenta noted that testing for MRD can help physicians determine if a cancer treatment has been successful and help guide additional treatment decisions.

Illumina's Nicholas Naclerio, senior vice president of corporate and venture development and general manager, said that the partnership with Sequenta is "consistent with our strategy to support third-party IVD products on our sequencing platform."

In addition, Illumina also said that it participated in Sequenta's recent Series D funding round.

 

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.